CN107926930A - 一种精子冷冻液及其制备方法 - Google Patents
一种精子冷冻液及其制备方法 Download PDFInfo
- Publication number
- CN107926930A CN107926930A CN201711231907.9A CN201711231907A CN107926930A CN 107926930 A CN107926930 A CN 107926930A CN 201711231907 A CN201711231907 A CN 201711231907A CN 107926930 A CN107926930 A CN 107926930A
- Authority
- CN
- China
- Prior art keywords
- sperm
- concentration
- liquid
- sodium
- sperm freezing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 51
- 238000007710 freezing Methods 0.000 title claims abstract description 26
- 230000008014 freezing Effects 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000009938 salting Methods 0.000 claims abstract description 23
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 14
- 229930006000 Sucrose Natural products 0.000 claims abstract description 14
- 230000003115 biocidal effect Effects 0.000 claims abstract description 14
- 239000005720 sucrose Substances 0.000 claims abstract description 14
- 235000011187 glycerol Nutrition 0.000 claims abstract description 11
- 230000003204 osmotic effect Effects 0.000 claims description 12
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 11
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 9
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 9
- 238000005215 recombination Methods 0.000 claims description 9
- 230000006798 recombination Effects 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 7
- 239000007995 HEPES buffer Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 7
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims description 6
- 102000009027 Albumins Human genes 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000002158 endotoxin Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000005374 membrane filtration Methods 0.000 claims description 6
- 239000001540 sodium lactate Substances 0.000 claims description 6
- 235000011088 sodium lactate Nutrition 0.000 claims description 6
- 229940005581 sodium lactate Drugs 0.000 claims description 6
- 229940054269 sodium pyruvate Drugs 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000007993 MOPS buffer Substances 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical group C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000002459 blastocyst Anatomy 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- 229910001424 calcium ion Inorganic materials 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 210000002257 embryonic structure Anatomy 0.000 claims description 3
- 229960002518 gentamicin Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 claims description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229940050528 albumin Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229960001031 glucose Drugs 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 7
- 210000001550 testis Anatomy 0.000 abstract description 6
- 230000001850 reproductive effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 230000004720 fertilization Effects 0.000 abstract description 2
- 238000000034 method Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 208000034874 Product colour issue Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013569 fruit product Nutrition 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0215—Disinfecting agents, e.g. antimicrobials for preserving living parts
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及一种精子冷冻液及其制备方法,属于人类辅助生殖技术领域。所述精子冷冻液是将甘油以20‑30%的浓度溶解于含有蔗糖、抗菌素、指示剂的盐溶液中配制而成。本发明所述的精子冷冻液中添加了甘油和蔗糖,甘油和蔗糖作为细胞保护剂,不仅可以温和有效地保护精子的活力和DNA的完整性,还能保护睾丸组织细胞的活性,进而保护睾丸内精子的活力,提高精子的受精率,同时,也为辅助生殖技术的安全性提供了有力保证。
Description
技术领域
本发明涉及一种精子冷冻液及其制备方法,属于人类辅助生殖技术领域。
背景技术
人类辅助生殖技术中,要通过对精子和睾丸活检组织冷冻,以保护精子的活力及其质膜完整性。常规的精子冷冻液是以HEPES或者MOPS盐溶液为缓冲的蛋黄溶液,不能有效地保精子的活力和完整性,尤其对活检睾丸组织的保存不够完好。
发明内容
本发明的目的在于,提供一种各项质控达标的精子冷冻液,不仅可以有效地改善精子的活力,提高冷冻精子人工授精(IUI)的成功率,而且也为辅助生殖技术的安全性提供了有力保证。
为解决上述问题,本发明所采用的技术方案是:
一种精子冷冻液,其特征在于:将甘油以20-30%的浓度溶解于含有蔗糖、抗菌素、指示剂的盐溶液中配制而成。
优选的:所述蔗糖的浓度为0.1-0.3mol/L。
优选的:抗菌素为庆大霉素,浓度为5-11μg/ml。
优选的:所述指示剂为酚红,浓度9-10μg/ml。
优选的:所述盐溶液是以HEPES或者MOPS为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、白蛋白为能量物质的化合物培养溶液;其中包含:氯化钠98.11-102.00mmol/L、氯化钾4.55-4.70mmol/L、硫酸镁0.18-0.22mmol/L、氯化钙1.92-2.12mmol/L、碳酸氢钠3.90-4.10mmol/L、HEPES或者MOPS19.99-22.00mmol/L、葡萄糖2.68-2.88mmol/L、丙酮酸钠0.31-0.33mmol/L、乳酸钠21.11-21.66mmol/L、磷酸二氢钾0.36-0.39mmol/L;
所述白蛋白为重组人血清白蛋白,是采用医疗级的重组人血清白蛋白干粉溶解于在盐水溶液中制备而成,终浓度为15-20mg/ml。
所述精子冷冻液的制备方法,包括以下步骤:
1、称量好各种组分,备用;
2、配制盐溶液:称量好的组分中,先将除了抗菌素、指示剂、碳酸氢钠以外的各组分溶于超纯注射级用水中,溶解过程中遵循先固体后液体的原则;所述超纯注射级用水经0.1-0.3μM滤膜过滤,内毒素<0.015EU/ml;然后,依次加入称量好的抗菌素、指示剂、碳酸氢钠,制得盐溶液;
3、检测步骤2所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250-275mOsm/Kg,所述pH值保持为7.0-7.4;
4、按照预配置的容量,配制蔗糖的工作浓度为0.1-0.3mol/L;
5、按照预配置的容量,将终浓度为15-20mg/ml的重组人血清白蛋白补充到盐溶液中;
6、将甘油以20-30%的工作浓度溶解于步骤5制得的盐溶液中,到充分溶解止;
7、将步骤6所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、30-37℃条件下pH值:7.20-7.45;
B、渗透压:1720-2020mOsm/Kg;
C、内毒素:<0.15EU/ml;
D、一细胞鼠胚培养到96小时:≥80%的囊胚形成率;
8、将配置好的溶液在百级GMP车间进行无菌分装和标签。
有益效果:本发明所述的精子冷冻液中添加了甘油和蔗糖,甘油和蔗糖作为细胞保护剂,不仅可以温和有效地保护精子的活力和DNA的完整性,还能保护睾丸组织细胞的活性,进而保护睾丸内精子的活力,提高精子的受精率,同时,也为辅助生殖技术的安全性提供了有力保证。
具体实施方式
下面结合具体实施实施方式对本发明做进一步说明。
本发明所述的精子冷冻液,是将甘油以20-30%的浓度溶解于含有蔗糖、抗菌素、指示剂的盐溶液中配制而成。
所述蔗糖的浓度为0.1-0.3mol/L;抗菌素为庆大霉素,浓度为5-11μg/ml;所述指示剂为酚红,浓度9-10μg/ml。
所述盐溶液是以HEPES或者MOPS为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、白蛋白为能量物质的化合物培养溶液;其中包含:氯化钠98.11-102.00mmol/L、氯化钾4.55-4.70mmol/L、硫酸镁0.18-0.22mmol/L、氯化钙1.92-2.12mmol/L、碳酸氢钠3.90-4.10mmol/L、HEPES或者MOPS19.99-22.00mmol/L、葡萄糖2.68-2.88mmol/L、丙酮酸钠0.31-0.33mmol/L、乳酸钠21.11-21.66mmol/L、磷酸二氢钾0.36-0.39mmol/L;
所述白蛋白为重组人血清白蛋白,是采用医疗级的重组人血清白蛋白干粉溶解于在盐水溶液中制备而成,终浓度为15-20mg/ml。
所述精子冷冻液的制备方法,包括以下步骤:
1、称量好各种组分,备用;
2、配制盐溶液:称量好的组分中,先将除了抗菌素、指示剂、碳酸氢钠以外的各组分溶于超纯注射级用水中,溶解过程中遵循先固体后液体的原则;所述超纯注射级用水经0.1-0.3μM滤膜过滤,内毒素<0.015EU/ml;然后,依次加入称量好的抗菌素、指示剂、碳酸氢钠,制得盐溶液;
3、检测步骤2所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250-275mOsm/Kg,所述pH值保持为7.0-7.4;
4、按照预配置的容量,配制蔗糖的工作浓度为0.1-0.3mol/L;
5、按照预配置的容量,将终浓度为15-20mg/ml的重组人血清白蛋白补充到盐溶液中;
6、将甘油以20-30%的工作浓度溶解于步骤5制得的盐溶液中,到充分溶解止;
7、将步骤6所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、30-37℃条件下pH值:7.20-7.45;
B、渗透压:1720-2020mOsm/Kg;
C、内毒素:<0.15EU/ml;
D、一细胞鼠胚培养到96小时:≥80%的囊胚形成率;
8、将配置好的溶液在百级GMP车间进行无菌分装和标签。
【存储说明和稳定性】
存储:将分装好的精子冷冻液存放于2℃-8℃,使用前移至室温(20-25℃)。应尽可能减少液体暴露于CO2的环境,防止7.0或更低的pH水平。不要暴露在高于39℃的温度下。
稳定性:可以直到标签上显示的到期日期。使用无菌程序除去所需体积的产品,一旦移除,不要将任何量的产品返回原始容器;如果产品变色、浑浊或有微生物污染迹象,请勿使用。
为避免污染问题,使用无菌技术进行处理,并在完成操作后丢弃瓶子或小瓶中剩余的任何多余产品。
【具体使用方法】
1、在禁欲2至3天后通过手淫收集精液,使样品在室温或37℃液化30分钟。
2、解冻一小瓶精子冷冻液等分试样,平衡至室温或37℃;为达到更好的效果在该步中可加入抗生素。
3、液化的样品转移到无菌的15mL锥形离心管中;测定试样体积,并逐滴加入适当体积的解冻的精子冷冻液,直到样品与培养基之比达到3∶1;例如,对于每1mL样品加入0.33mL培养基。
4、将样品-培养基混合物等分至已标记的冷冻管或吸管中;为了避免其因膨胀而溢出,不可向冷冻管内加入过多的液体。
5、精子样品可直接冷冻,也可使用程序化的冷冻设备或蒸汽冷冻程序进行缓慢冷冻。
6、缓慢冷却的可选方案:将填充的冷冻管放置在铝架上;将铝架浸入室温水浴(即含有500mL水的塑料烧杯)中,然后再将烧杯置于冰箱(2至8℃)中60至90分钟,进行冷冻。
7、冷冻程序结束后,将精子冷冻管置于液氮中保存。
Claims (6)
1.一种精子冷冻液,其特征在于:将甘油以20-30%的浓度溶解于含有蔗糖、抗菌素、指示剂的盐溶液中配制而成。
2.根据权利要求1所述的精子冷冻液,其特征在于:所述蔗糖的浓度为0.1-0.3mol/L。
3.根据权利要求2所述的精子冷冻液,其特征在于:抗菌素为庆大霉素,浓度为5-11μg/ml。
4.根据权利要求3所述的精子冷冻液,其特征在于:所述指示剂为酚红,浓度9-10μg/ml。
5.根据权利要求4所述的精子冷冻液,其特征在于:所述盐溶液是以HEPES或者MOPS为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、白蛋白为能量物质的化合物培养溶液;其中包含:氯化钠98.11-102.00mmol/L、氯化钾4.55-4.70mmol/L、硫酸镁0.18-0.22mmol/L、氯化钙1.92-2.12mmol/L、碳酸氢钠3.90-4.10mmol/L、HEPES或者MOPS19.99-22.00mmol/L、葡萄糖2.68-2.88mmol/L、丙酮酸钠0.31-0.33mmol/L、乳酸钠21.11-21.66mmol/L、磷酸二氢钾0.36-0.39mmol/L;
所述白蛋白为重组人血清白蛋白,是采用医疗级的重组人血清白蛋白干粉溶解于在盐水溶液中制备而成,终浓度为15-20mg/ml。
6.如权利要求5所述精子冷冻液的制备方法,其特征在于:包括以下步骤:
(1)称量好各种组分,备用;
(2)配制盐溶液:称量好的组分中,先将除了抗菌素、指示剂、碳酸氢钠以外的各组分溶于超纯注射级用水中,溶解过程中遵循先固体后液体的原则;所述超纯注射级用水经0.1-0.3μM滤膜过滤,内毒素<0.015EU/ml;然后,依次加入称量好的抗菌素、指示剂、碳酸氢钠,制得盐溶液;
(3)检测步骤(2)所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250-275mOsm/Kg,所述pH值保持为7.0-7.4;
(4)按照预配置的容量,配制蔗糖的工作浓度为0.1-0.3mol/L;
(5)按照预配置的容量,将终浓度为15-20mg/ml的重组人血清白蛋白补充到盐溶液中;
(6)将甘油以20-30%的工作浓度溶解于步骤(5)制得的盐溶液中,到充分溶解止;
(7)将步骤(6)所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、30-37℃条件下pH值:7.20-7.45;
B、渗透压:1720-2020mOsm/Kg;
C、内毒素:<0.15EU/ml;
D、一细胞鼠胚培养到96小时:≥80%的囊胚形成率;
(8)将配置好的溶液在百级GMP车间进行无菌分装和标签。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711231907.9A CN107926930A (zh) | 2017-11-22 | 2017-11-22 | 一种精子冷冻液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711231907.9A CN107926930A (zh) | 2017-11-22 | 2017-11-22 | 一种精子冷冻液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107926930A true CN107926930A (zh) | 2018-04-20 |
Family
ID=61946864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711231907.9A Pending CN107926930A (zh) | 2017-11-22 | 2017-11-22 | 一种精子冷冻液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107926930A (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108739796A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物(中国)股份有限公司 | 一种玻璃化冷冻液及其制备方法 |
CN108753698A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物(中国)股份有限公司 | 一种玻璃化解冻液及其制备方法 |
CN108849851A (zh) * | 2018-05-16 | 2018-11-23 | 瑞柏生物(中国)股份有限公司 | 一种聚乙烯吡咯烷酮溶液及其制备方法 |
CN109329272A (zh) * | 2018-11-23 | 2019-02-15 | 北京太东生物科技有限公司 | 一种精子冻存液及其制备方法和应用 |
CN111202051A (zh) * | 2020-02-26 | 2020-05-29 | 东蕴医疗科技(上海)有限公司 | 一种用于人类辅助生殖的精子冷冻液及其制备方法 |
CN111436421A (zh) * | 2020-05-21 | 2020-07-24 | 新乡医学院三全学院 | 一种人类精子冷冻保存方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013074A1 (en) * | 2000-12-04 | 2003-01-16 | Kenzo Bamba | Cell-preservation liquid and method of preserving cells by using the liquid |
CN104130974A (zh) * | 2014-08-08 | 2014-11-05 | 山东威高新生医疗器械有限公司 | 精子制动液及其制备方法 |
CN107027741A (zh) * | 2017-05-24 | 2017-08-11 | 四川大学华西第二医院 | 一种不含卵黄的人精子冷冻保护液及保存方法 |
-
2017
- 2017-11-22 CN CN201711231907.9A patent/CN107926930A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030013074A1 (en) * | 2000-12-04 | 2003-01-16 | Kenzo Bamba | Cell-preservation liquid and method of preserving cells by using the liquid |
CN104130974A (zh) * | 2014-08-08 | 2014-11-05 | 山东威高新生医疗器械有限公司 | 精子制动液及其制备方法 |
CN107027741A (zh) * | 2017-05-24 | 2017-08-11 | 四川大学华西第二医院 | 一种不含卵黄的人精子冷冻保护液及保存方法 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108849851A (zh) * | 2018-05-16 | 2018-11-23 | 瑞柏生物(中国)股份有限公司 | 一种聚乙烯吡咯烷酮溶液及其制备方法 |
CN108739796A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物(中国)股份有限公司 | 一种玻璃化冷冻液及其制备方法 |
CN108753698A (zh) * | 2018-06-05 | 2018-11-06 | 瑞柏生物(中国)股份有限公司 | 一种玻璃化解冻液及其制备方法 |
CN109329272A (zh) * | 2018-11-23 | 2019-02-15 | 北京太东生物科技有限公司 | 一种精子冻存液及其制备方法和应用 |
CN111202051A (zh) * | 2020-02-26 | 2020-05-29 | 东蕴医疗科技(上海)有限公司 | 一种用于人类辅助生殖的精子冷冻液及其制备方法 |
CN111436421A (zh) * | 2020-05-21 | 2020-07-24 | 新乡医学院三全学院 | 一种人类精子冷冻保存方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107926930A (zh) | 一种精子冷冻液及其制备方法 | |
Mahadevan et al. | Effect of cryoprotective media and dilution methods on the preservation of human spermatozoa | |
Isachenko et al. | Acrosomal status and mitochondrial activity of human spermatozoa vitrified with sucrose | |
CN108739796A (zh) | 一种玻璃化冷冻液及其制备方法 | |
CN107988149A (zh) | 一种精子活力液及其制备方法 | |
Galarza et al. | Two-step accelerating freezing protocol yields a better motility, membranes and DNA integrities of thawed ram sperm than three-steps freezing protocols | |
CN110839615B (zh) | 一种卵母细胞冷冻保存液及保存方法 | |
CN106916220A (zh) | 一种重组人血清白蛋白溶液及其制备方法 | |
CN108753698A (zh) | 一种玻璃化解冻液及其制备方法 | |
Turri et al. | Effect of testicle postmortem storage on goat frozen-thawed epididymal sperm quality as a tool to improve genebanking in local breeds | |
CN108728403A (zh) | 一种卵裂培养液及其制备方法 | |
Batissaco et al. | Cholesterol-loaded cyclodextrin is efficient in preserving sperm quality of cryopreserved ram semen with low freezability | |
CN107027741B (zh) | 一种不含卵黄的人精子冷冻保护液及保存方法 | |
US20120301868A1 (en) | Extender for a semen suspension | |
Khatun et al. | In vitro assessment of tris egg yolk and soybean lecithin based extenders for cryopreservation of crossbred ram semen | |
EP2611290B1 (en) | Method for cryopreservation of human spermatozoa free from seminal plasma using a fast and simple aseptic vitrification-devitrification process | |
CN106916800A (zh) | 一种重组人颗粒细胞酶溶液及其制备方法 | |
CN115152740A (zh) | 一种猪组织长期保存液及其使用方法 | |
CN110115265A (zh) | 一种胚胎玻璃化冷冻液 | |
CN108624551A (zh) | 一种受精培养液及其制备方法 | |
CN108728402A (zh) | 一种活检培养液及其制备方法 | |
Chen et al. | Cryopreservation of woody species | |
Suksai et al. | Effects of trehalose and sucrose on human sperm motility, vitality and morphology after cryopreservation | |
Yang et al. | Cryoinjury in human granulocytes and cytoplasts | |
JP2008104407A (ja) | 細胞保存方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180420 |
|
RJ01 | Rejection of invention patent application after publication |